C71T
CANCELLED SECTION 71
06/05/2026
Back to search
Official data from USPTO
TSUMOYLE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
06/30/2026
Classification
Registered
Trademark type
Word
Nice classes
3, 5
Filing date
09/18/2018
Registration date
11/19/2019
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/05/2026
Last transaction
06/30/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
RUTLAND, BARBARA A
Law office
L10
Current location
PETITIONS OFFICE
Holders and representatives
Holders
Clinuvel (UK) Ltd
Representatives
Michelle P. Ciotola Cantor Colburn LLP
Technical classification
Nice Classes
Class 3Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 3
Non-medicated skin care preparations; cosmetic preparations for skin care; cosmetic preparations for skin carebased on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetic oils; cosmetic skin creams; skin care creamslotions and oils for cosmetic purposes; wrinkle removing skin care preparations; cosmetic sunscreen preparations; waterproof sunscreen; sunscreen preparations; sunscreen creams and lotions; cosmetics for protecting the skin from sunburn; sunblock lotions; cosmetic sun barriers; sun creams; cosmetic preparations for protecting the skin from the sun's rays; sun care lotions; cosmetic compounds for skin care after exposure to the sun's rays; after-sun milkscreamslotions and moisturizers; sun skin bronzers; sun-tanning preparations; cosmetics for tanning the skin including preparations for tanning without sunlightcontaining analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetics for tanning the skin including preparations for tanning without sunlightnot containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; cosmetic self-tanning preparations; self -tanning creams and lotions for cosmetic purposes; suntan creamslotionsoils and gels; non-medicated skin rejuvenation preparationscreamslotionsmoisturizersgelsbalmsserumsoilstonerscleaners and peels; non-medicated skin rejuvenation productscreamslotionsmoisturizersgelsbalmsserumsoilstonerscleaners and peels with and without analogues of alpha-melanocyte stimulating hormone (alpha-MSH); non-medicated antiaging skincare preparations; antiaging creamslotionsmoisturizersgelsbalms and serums; skin cleansing creamslotionsmilksfoamsgels and masks for cosmetic purposes
Class 5
Pharmaceuticals for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin wounds; pharmaceuticals for skin care and for the treatment of skin and skin relating conditions and disorders based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; pharmaceutical drugs for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin wounds; pharmaceutical drugs for skin care and for the treatment of skin and skin relating conditions and disorders based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; pharmaceutical preparations for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin wounds; pharmaceutical preparations for skin care and for the treatment of skin and skin relating conditions and disorders based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; sun tanning preparations for pharmaceutical purposescontaining analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; sun tanning preparations for pharmaceutical purposesnot containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; medicated dermatological preparations; dermatological pharmaceutical substances; dermatological pharmaceutical products; medicinal creams for the protection of the skin; skin care creams for medical use; skin care preparations for medical use; medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; chemical and biological preparationssubstancesreagents and compounds for use in dermatologyfor skin carefor the treatment of skin and skin relating conditions and disordersfor the treatment of damaged skin and tissuefor the treatment of sunburnfor the protection of the dermis and epidermisfor skin woundsall used for the delivery and storage of pharmaceuticals containing analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide
Publications
History of USPTO decisions and trademark events.
30 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/19/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/27/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/11/2020
FIMP
FINAL DISPOSITION PROCESSED
03/11/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/19/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
11/19/2019
CHPB
POST PUBLICATION AMENDMENT - ENTERED
10/09/2019
APET
ASSIGNED TO PETITION STAFF
10/09/2019
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
09/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/03/2019
PUBO
PUBLISHED FOR OPPOSITION
09/03/2019
GPNX
NOTIFICATION PROCESSED BY IB
08/30/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/14/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/14/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/14/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/29/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/20/2019
ALIE
ASSIGNED TO LIE
07/16/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/11/2019
RFNT
REFUSAL PROCESSED BY IB
02/02/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/16/2019
RFRR
REFUSAL PROCESSED BY MPU
01/16/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/05/2019
CNRT
NON-FINAL ACTION WRITTEN
01/04/2019
DOCK
ASSIGNED TO EXAMINER
12/28/2018
MAFR
APPLICATION FILING RECEIPT MAILED
11/30/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/26/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/22/2018
Continuous trademark protection
Get notified about every new filing that threatens TSUMOYLE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.